DR. ANDREW H KANG, MD
Osteopathic Medicine at Nonconnah Blvd, Memphis, TN

6423315, Jul 23, 2002

Apr 20, 1995

08/425175

Linda K. Myers - Memphis TN
Jerome M. Seyer - Memphis TN
Andrew H. Kang - Memphis TN

The University of Tennessee Research Corp. - Knoxville TN

A61K 3808

4241851, 4241841, 4241921, 424810, 4241981, 514 12, 514 17, 514 15, 514 13, 514 14, 514 16, 514825, 530300, 530326, 530327, 530328, 530329, 530356, 530806, 530324, 530325

Peptides that are capable of suppressing autoimmune arthritis are disclosed. The polypeptides described by the present invention which are capable of suppressing autoimmune arthritis in mammals include analogues of CII 245-270. The peptides do not provoke a material immunogenic response from T cells, and thus are useful therapeutic agents for suppressing autoimmune arthritis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, spondylo arthritis, relapsing polychondritis and other connective tissue diseases. A method of surpressing autoimmune arthritis in mammals is also provided by the present invention.

5962025, Oct 5, 1999

Jul 16, 1996

8/682021

Laura Carbone - Memphis TN
Andrew H. Kang - Memphis TN
Kevin McKown - Memphis TN
Arnold E. Postlethwaite - Memphis TN
Jerome M. Seyer - Virginia Beach VA

The University of Tennessee Research Corporation - Knoxville TN

A61K 3512

424520

The present invention is directed to a method and pharmaceutical formulations for the treatment of systemic sclerosis in mammals, by oral administration of collagen, including type I collagen, or biologically active peptide fragments thereof.

5160483, Nov 3, 1992

May 7, 1991

7/697642

Arnold E. Postlethwaite - Eads TN
Jerome M. Seyer - Memphis TN
Andrew H. Kang - Memphis TN

The University of Tennessee Research Corporation - Knoxville TN

A61K 3700, A61K 4505

424 851

A method and composition for promoting the healing of an open wound, such as a fresh surgical incision, a decubitus ulcer, or a diabetes ulcer. The method includes applying to the wound a therapeutically effective amount of a composition comprising a protein fragment of tumor necrosis factor. alpha. (TNF-. alpha. ) including amino acids 31 through 68 SEQ ID NO. : 1. The composition may be applied topically or injected locally into a wound or ulcer site. A preferred composition includes a carrier medium selected from sterile water, sterile saline, and albumin. Topical formulations are administered as sprays, gels, ointments or salves.

5436228, Jul 25, 1995

Sep 28, 1993

8/127909

Arnold E. Postlethwaite - Eads TN
Jerome Seyer - Memphis TN
Andrew Kang - Memphis TN

A61K 3800, C07K 500, C07K 700, C07K 1700

514 12

Peptides corresponding to an no acid sequences in the C-terminal region of TGF-. beta. are provided. The peptides all contain at least a seven amino acid sequence substantially corresponding to the amino acid sequence of TGF-. beta. 1 amino acids 368-374: VYYVGRK, as well as homologs and analogs thereof. The peptides have chemotactic activity towards fibroblasts, monocytes and neutrophils and induce fibroblast proliferation and collagen synthesis. The peptides may be used in compositions and methods for promoting wound healing.

5824647, Oct 20, 1998

Jun 1, 1995

8/457353

Arnold E. Postlethwaite - Eads TN
Jerome Seyer - Memphis TN
Andrew Kang - Memphis TN

A61K 3800, A61K 3804, C07K 500, C07K 700

514 13

Peptides corresponding to amino acid sequences in the C-terminal region of TGF-. beta. are provided. The peptides all contain at least a seven amino acid sequence substantially corresponding to the amino acid sequence of TGF-. beta. 1 amino acids 368-374: VYYVGRK, as well as homologs and analogs thereof. The peptides have chemotactic activity towards fibroblasts, monocytes and neutrophils and induce fibroblast proliferation and collagen synthesis. The peptides may be used in compositions and methods for promoting wound healing.

2011019, Aug 11, 2011

Oct 28, 2010

12/914823

Arnold R. Postlewaite - Eads TN, US
Andrew H. Kang - Memphis TN, US
Linda K. Myers - Memphis TN, US

arGentis Pharmaceuticals, LLC - Memphis TN

A61K 38/17, C07K 14/435, A61P 19/02

514 166, 530324

One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.

2010017, Jul 15, 2010

Mar 29, 2010

12/749141

Arnold E. Postlethwaite - Eads TN, US
Andrew H. Kang - Memphis TN, US

The University of Tennessee Research Foundation - Memphis TN

A61K 38/39, A61P 43/00

514 12

The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.

7718765, May 18, 2010

Nov 16, 2006

11/600525

Arnold E. Postlethwaite - Eads TN, US
Andrew H. Kang - Memphis TN, US

The University of Tennessee Research Foundation - Memphis TN

C07K 14/00, A61K 38/00

530300, 514 2, 4241841

The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.